StockNews.com Initiates Coverage on NovaBay Pharmaceuticals (NYSE:NBY)

Equities research analysts at StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a report released on Sunday. The firm set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets cut their price target on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a report on Monday, November 11th.

NovaBay Pharmaceuticals Price Performance

NovaBay Pharmaceuticals stock opened at $0.76 on Friday. The stock has a market capitalization of $3.71 million, a PE ratio of -0.01 and a beta of 0.65. The business has a 50 day simple moving average of $0.62 and a 200-day simple moving average of $0.81. NovaBay Pharmaceuticals has a 12 month low of $0.36 and a 12 month high of $9.08.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.